Learn how Syngene achieves manufacturing milestones in Biologics using a systemic approach to 100% ‘first-time right’ technology transfer.

How and why CROs/CDMOs are better positioned to bridge the gap between vaccine demand and supply, safely and at speed.

Synthetic oligonucleotides have emerged as an important modality for diagnostics and potential therapy option for COVID-19.

Antisense Oligonucleotides is gaining momentum as a treatment modality to correct faulty protein expression by non-conventional means i.e., splicing modifications.

At Syngene, we have developed a roadmap across pre-IND, IND and NDA that seamlessly integrate the various pre-clinical studies — thereby accelerating the initiation of Clinical trials.

Syngene’s dedicated  model is the equivalent of having access to a full-fledged pharma company, housed in a single campus with capabilities across small and large molecules.

By identifying COVID-19 positive cases early on,  particularly those that are asymtomatic,  we can restrict further transmission of this deadly virus.

Syngene’s 7-phase integrated CMC strategy helps expedite IND/IMPD filings and FIH studies. As a result, the  typical time from clinical candidate to regulatory filing is  just 11 months.